Cutaneous adverse events to immune checkpoint inhibitors in pediatric populations: A retrospective cohort study

McCormack, Lindsay; Thompson, Leah L.; Chang, Michael S.; Polyakov, Nicole J.; Song, Hannah; Chen, Shuo; Huang, Jennifer T.

doi:10.1016/j.jaad.2020.11.033

Cited by 2 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two retrospective reviews by Cacciotti et al 91 . and McCormack et al 92 . noted similar rates of cAEs, including rash in 15.8%–27% and mucositis in 1%.…”

Section: Resultsmentioning

confidence: 90%

See 1 more Smart Citation

Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review

Liu

Teng

Spunt

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essential to optimize ongoing cancerdirected therapy and improve quality of life. This systematic review of published studies summarizes dermatologic toxicities to targeted anticancer treatments and immune checkpoint inhibitors.

show abstract

“…Two retrospective reviews by Cacciotti et al 91 . and McCormack et al 92 . noted similar rates of cAEs, including rash in 15.8%–27% and mucositis in 1%.…”

Section: Resultsmentioning

confidence: 90%

“…also noted wound dehiscence/infection in one patient (0.9%). McCormack et al 92 . reported specific cutaneous reaction patterns associated with ICIs, including xerosis (3.9%), pruritus (2.6%), acneiform eruption (2.6%), vitiligo (2.6%), psoriasiform eruption (1.3%), and urticarial eruption (1.3%).…”

Section: Resultsmentioning

confidence: 99%

Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review

Liu

Teng

Spunt

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…McCormack et al 6 and Cacocciotti et al 7 reported a 32% and 35% incidence of cutaneous irAEs in the pediatric population, respectively. The most common type of eruption reported in the pediatric population is a “maculopapular” rash, 4–7 similar to the adult population. However, other ICI‐induced eruptions frequently reported in the adult population, such as lichenoid and bullous eruptions, have not been well‐described in children.…”

Section: Discussionmentioning

confidence: 99%

“…Retrospective studies, however, have demonstrated comparable rates of ICI‐related cutaneous irAEs among adults and children. McCormack et al 6 and Cacocciotti et al 7 reported a 32% and 35% incidence of cutaneous irAEs in the pediatric population, respectively. The most common type of eruption reported in the pediatric population is a “maculopapular” rash, 4–7 similar to the adult population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of severe nivolumab‐induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma

Mueller

Cordisco

Scott

et al. 2022

Pediatric Dermatology

View full text Add to dashboard Cite

Dermatologic reactions are among the most common adverse events of antiprogrammed cell death-1 (anti-PD-1) monoclonal antibodies agents and include maculopapular rash, psoriasiform rash, lichenoid eruptions, autoimmune bullous disorders, and vitiligo. Here, we present a case of a 12-year-old African American male with metastatic spitzoid melanoma treated with nivolumab who developed a mild lichenoid eruption that progressed to a severe case of lichen planus pemphigoides (LPP).Management was complex given the patient's age and history and included hospitalization for intravenous steroids, an intensive topical steroid regimen, methotrexate, and discontinuation of nivolumab. This case illustrates a rare but dramatic progression from a mild LP-like eruption to severe bullous lichenoid eruption, most consistent with LPP, as well as the diagnostic and treatment challenges in the setting of a pediatric patient on nivolumab.

show abstract

Cutaneous adverse events to immune checkpoint inhibitors in pediatric populations: A retrospective cohort study

Cited by 2 publications

References 5 publications

Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review

Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review

A case of severe nivolumab‐induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma

Contact Info

Product

Resources

About